Novel approaches to testing for sexually transmitted infections, including HIV and hepatitis B and C in Europe
This report focuses on novel approaches to testing for sexually transmitted infections (STIs), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) that are relevant for the prevention and control of these infections at EU/EEA level.
‘Novel approaches’ captures both technical advances in STI, HIV, HBV and HCV tests as well as new opportunities for initiating and conducting testing and managing results, treatment and surveillance that the changes in technology facilitate.
Effective testing strategies are vital for the control of sexually transmitted infections (STI), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) as accurate testing allows treatment of those infected and subsequent reduction in infectiousness. In addition, it leads to a reduction of clinical consequences, identification and treatment of potentially infected partners as well as opportunities for health promotion and behaviour modification due to awareness of infection.Recent changes in the field of testing for STI, HIV, HBV and HCV include the widespread implementation of nucleic acid amplification technologies (NAATs) for chlamydia and gonorrhoea diagnosis or the development of HIV screening tests that are easy to use and give a result almost immediately. Novel approaches in testing cover both technical advances in STI, HIV and hepatitis B and C tests as well as new opportunities for initiating and conducting testing and managing results, treatment and surveillance that changes in technology facilitate. The report Novel approaches to testing for sexually transmitted infections, including HIV and hepatitis B and C in Europe concludes that new testing technologies combined with modern information and communication systems will enable the development of novel testing pathways. These novel approaches have the potential to improve access to (and hence the uptake of) testing among individuals and population groups at risk of infections as well as increase the proportion of infected individuals treated earlier in infection. These novel approaches will have a clinical impact by improving the prognosis for those with infections as well as the public health impact by reducing onward transmission and thus incidence and prevalence of infection.
ECDC Evidence Brief: Pre-exposure prophylaxis for HIV prevention in Europe and Central Asia
28 Nov 2019 - This evidence brief summarises key issues and priorities for action in Europe and Central Asia on PrEP. It is largely based on data collected in 2018 and 2019 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration. The monitoring questionnaire was disseminated to the 53 countries that are part of the WHO European Region, plus Kosovo and Liechtenstein via an online survey.
HIV testing, Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2018 progress report
27 Nov 2019 - This report presents the situation of HIV testing in Europe and Central Asia. It summarises data on implementation of national guidelines that shape HIV testing policies, the provision and uptake of HIV testing services in general and among key populations, and efforts being made to widen engagement with HIV testing and reduce late diagnosis.
External quality assessment of laboratory performance – European Antimicrobial Resistance Surveillance Network (EARS-Net), 2018
22 Nov 2019 - This report provides an analysis of the external quality assessment (EQA) performance with antimicrobial susceptibility testing (AST) of laboratories participating in the European Antimicrobial Resistance Surveillance Network in 2018. A total of 860 laboratories (1 – 114 per country) from 30 EU/EEA countries participated in the EQA exercise. Six bacterial strains were used: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecium and Streptococcus pneumoniae.